April 26, 2026 Content Writer: Author Correction: High-Dose Nusinersen for Spinal Muscular Atrophy – Phase 3 Randomized Trial Correction
January 28, 2026 Intrathecal Onasemnogene abeparvovec for Spinal Muscular Atrophy Treatment-Experienced Patients
December 9, 2025 Onasemnogene abeparvovec for Treatment-Experienced SMA Patients: Phase 3b Trial Results
